Clinical trials

Microbiome
#Clinical trials #EnteroBiotix #Gut microbiome #Irritable Bowel Syndrome

New positive microbiome results for IBS-C

EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class drugs for gut health, has announced positive initial results with EBX-102-02, the company’s next-generation full-spectrum microbiome product, from the TrIuMPH Phase IIa clinical trial in adults with irritable bowel syndrome with constipation (IBS-C). The multicentre, randomised, double-blind, placebo-controlled TrIuMPH (Treating IBS with an… Read More

#News

#Clinical trial design #Clinical trials #Drug development #Drug discovery

New DDW Highlights podcast: 17 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials of all stages have dominated the DDW news section this week. All… Read More

#News

#Clinical trial design #Clinical trials #Drug development #Drug discovery

This week in drug discovery (10-14 March) 

News round-up for 10-14 March by DDW Senior Digital Content Editor Diana Spencer. Clinical trials of all stages have dominated the DDW news section this week. All the stories represent a significant step forward for drug discovery, either due to the innovative nature of the therapies being studied,… Read More

#News

#AAV #Clinical trials #Eye health #Gene therapy #Stargardt disease

First patient dosed in gene therapy study for Stargardt disease

SpliceBio has dosed the first patient in the Phase I/II ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector, for the treatment of Stargardt disease. Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene. It is the most common form of juvenile macular degeneration,… Read More

#News

Acute lymphoblastic leukemia
#Bantam Pharmaceutical #Clinical trials #Health Canada #Lymphoma #Small molecules

Trial evaluating treatment for R/R mature B-cell lymphomas

Bantam Pharmaceutical, a company targeting selective modulation of mitochondrial dynamics in cancer, is proceeding with a Phase I clinical trial evaluating BTM-3566 in relapsed/refractory (R/R) mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical… Read More

#Cancer Research #News

Laboratory research
#Clinical trials #Genetic diseases #Rare disease #Washington University School of Medicine

New US centre for rare diseases to promote drug research

Washington University School of Medicine in St Louis has launched the Center for Rare, Undiagnosed and Genetic Diseases, supported by an $8.5 million grant from Children’s Discovery Institute (CDI), a partnership with St Louis Children’s Hospital, St Louis Children’s Hospital Foundation and WashU Medicine.   The new centre… Read More

#News

Approval stamp
#Alopecia #Alys Pharmaceuticals #Clinical trials #FDA #Health Canada #Investigational New Drug (IND)

Clearance for first genetic medicine programme in dermatology

The US Food and Drug Administration (FDA) and Health Canada have cleared Alys Pharmaceuticals’ Investigational New Drug (IND) / Clinical Trial Application (CTA) for the study of ALY-101 in patients suffering from Alopecia Areata (AA). The Phase IIa trial will evaluate the safety and efficacy of ALY-101, an intradermal injectable… Read More

#News #Regulatory

#Breast cancer #Cancer research #Clinical trials #Solid tumours

New DDW Highlights episode: 27 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week that… Read More

#News

#Breast cancer #Cancer research #Clinical trials #Phesi

Breast cancer tops most-studied diseases, study finds 

Phesi has released the results of its annual global analysis of all clinical trials conducted in 2024, using data from its AI-driven Trial Accelerator platform (Figure 1). The analysis of 67,469 recruiting clinical trials reveals that breast cancer is the world’s most studied disease for the fourth consecutive year… Read More

#Cancer Research #News

Multiple myeloma
#Antibody drug conjugate (ADC) #Clinical trials #Heidelberg Pharma #Myeloma

Heidelberg Pharma progresses multiple myeloma ADC

Heidelberg Pharma is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Heidelberg uses the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin… Read More

#News

#Clinical trials #CNS #Drug development #Drug discovery #Rare disease

The difficulties of rare disease clinical trials

Late-stage biotech Minoryx is developing a therapy (leriglitazone) targeting patients with the rare progressive CNS disease cerebral adrenoleukodystrophy (cALD). If approved, it would give patients another choice of treatment options outside of stem cell transplants and gene therapies. Data presented last year for leriglitazone showed it stopped cALD disease progression… Read More

#Exclusive Content

#Biotechnology #Cancer research #Clinical trials #Drug development #Drug discovery #Drug targets #Opinion #Podcasts

The DDW Podcast: 2024 in review

As 2024 draws to a close, DDW’s Multimedia Editor and podcast host Megan Thomas rounds up all the free editorial episodes of the DDW podcast that were released. You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. DDW Highlights Innovative. Evolving. Developing. Busy. These… Read More

#News

#AACR #Cancer research #Clinical trials #Monotherapy #Recursion #Solid tumours

Encouraging response for monotherapy dose-escalation study

Recursion has reported initial monotherapy dose-escalation data from the Phase I/II study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumours. These results were presented after market close at an AACR Special Conference in Cancer Research. “Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive… Read More

#Cancer Research #News

UK on global map
#ABPI #Clinical trials #Life sciences #UK

UK starts to rebuild global position for industry clinical trials

A new report finds the UK’s global rankings for industry clinical trial delivery are improving.  However, further challenges must be overcome if the UK is to fight off fierce international competition to attract lucrative life science research.  In its annual report on the health of UK industry clinical trials, the… Read More

#Business & Investment #News #Trends & Analysis

#Clinical trials #Phase I trial #Phase II trial

New DDW Highlights episode: 2 December 2024

The latest episode of the DDW Highlights podcast is now available. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s leading news stories all feature early-stage clinical trials, including a short interfering RNA for cardiovascular disease,… Read More

#News

#Clinical trials #Phase I trial #Phase II trial

This week in drug discovery (25-29 November) 

News round-up for 25-29 November by DDW Senior Digital Content Editor Diana Spencer. This week’s leading news stories all feature early-stage clinical trials, including a short interfering RNA for cardiovascular disease, a new type of drug for type 2 diabetes, a gene therapy for Duchenne muscular dystrophy, a… Read More

#News